For: | Shengir M, Elgara M, Sebastiani G. Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond. World J Gastroenterol 2021; 27(17): 1959-1972 [PMID: 34007133 DOI: 10.3748/wjg.v27.i17.1959] |
---|---|
URL: | https://www.wjgnet.com/1948-5182/full/v27/i17/1959.htm |
Number | Citing Articles |
1 |
Evgeniy V. Kryukov, Dmitry V. Cherkashin, Vladimir V. Saluhov, Konstantin V. Matjushenko, Aleksey D. Sobolev, Nikolaj N. Shcherbina. Extrahepatic manifestations of chronic viral hepatitis C. Bulletin of the Russian Military Medical Academy 2022; 24(2): 341 doi: 10.17816/brmma103982
|
2 |
Suguru Kurokawa, Masato Yoneda, Yuji Ogawa, Yasushi Honda, Takaomi Kessoku, Kento Imajo, Satoru Saito, Atsushi Nakajima, Kikuko Hotta. Two differentially methylated region networks in nonalcoholic fatty liver disease, viral hepatitis, and hepatocellular carcinoma. BMC Gastroenterology 2022; 22(1) doi: 10.1186/s12876-022-02360-4
|
3 |
Malini M. Gandhi, Kim-Lien Nguyen, Jordan E. Lake, Diana Liao, Aleen Khodabakhshian, Mario Guerrero, Chrisandra L. Shufelt, C. Noel Bairey Merz, Wilbert C. Jordan, Eric S. Daar, Debika Bhattacharya, Kara W. Chew. Proprotein convertase subtisilin/kexin 9 levels decline with hepatitis C virus therapy in people with HIV/hepatitis C virus and correlate with inflammation. AIDS 2024; 38(3): 317 doi: 10.1097/QAD.0000000000003739
|
4 |
Zuzana Macek Jilkova, Komal Saleem, Samia Afzal, Thomas Decaens. Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV. Livers 2021; 1(4): 313 doi: 10.3390/livers1040024
|
5 |
Wesal Elgretli, Tianyan Chen, Nadine Kronfli, Giada Sebastiani. Hepatitis C Virus-Lipid Interplay: Pathogenesis and Clinical Impact. Biomedicines 2023; 11(2): 271 doi: 10.3390/biomedicines11020271
|
6 |
Jesus Torres-Flores, Nora A. Fierro. Are previous viral infections important for the COVID-19 outcomes?. Annals of Hepatology 2021; 25: 100554 doi: 10.1016/j.aohep.2021.100554
|